VCA Stocks

Apoptos Inc., an oncology research and development company, today announced that it has secured $28 million in funding.  It will be used to advance Apoptos’ portfolio of small molecule drugs that are directed at inducing tumor cell apoptosis, also known as programmed cell death.  Apoptos is pioneering its anticancer platforms in close collaborations with preeminent scientists in the fields of apoptosis and experimental cancer therapy. Evasion of apoptosis pathways is central to cancer cell survival and reactivation of these cell-death pathways offers attractive anticancer drug development opportunities. In addition to cancer, Apoptos’ technology also promises to have applications in other areas of medicine, including autoimmune diseases and inflammation.